Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Humulin 50/50 [patient package insert]. Indianapolis, IN: Eli Lilly and Company;2007 August.
Lilly USA, LLC. UPDATE: discontinuation of Humulin® 50/50 (50% Human Insulin
Isophane Suspension and 50% Human Insulin Injection [rDNA Origin]): Dear healthcare professional letter (12/2/2009). FDA Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm. Accessed December 23, 2009.
Eli Lilly and Company. Dear healthcare provider letter: important Discontinuation of Humulin® 50/50 (50% Human Insulin Isophane Suspension and 50% Human Insulin Injection [rDNA ORIGIN]) (June 2009). FDA Web site. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM176693.pdf. Accessed August 21, 2009.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed October 28, 2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click